| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Unité de Fabrication des Médicaments S.A Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.ت7.30 |
| 52 Week High | د.ت8.28 |
| 52 Week Low | د.ت6.85 |
| Beta | 0.049 |
| 1 Month Change | 0.41% |
| 3 Month Change | 1.39% |
| 1 Year Change | -2.54% |
| 3 Year Change | 7.20% |
| 5 Year Change | -29.06% |
| Change since IPO | -29.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| UMED | TN Pharmaceuticals | TN Market | |
|---|---|---|---|
| 7D | 1.7% | -2.8% | -0.5% |
| 1Y | -2.5% | 9.9% | 3.7% |
Return vs Industry: UMED underperformed the TN Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: UMED underperformed the TN Market which returned 3.7% over the past year.
Price Volatility
| UMED volatility | |
|---|---|
| UMED Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 3.0% |
| 10% most volatile stocks in TN Market | 4.6% |
| 10% least volatile stocks in TN Market | 2.1% |
Stable Share Price: UMED has not had significant price volatility in the past 3 months.
Volatility Over Time: UMED's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Ridha Charfeddine | www.unimed.com.tn |
Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company offers Opthalmic, ENT, and inhalation solutions, infusion solutions, injectable fluids and penicillin, and cephalosporin powders, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It manufactures medicines for third party laboratories principals.
Unité de Fabrication des Médicaments S.A Fundamentals Summary
| UMED fundamental statistics | |
|---|---|
| Market cap | د.ت233.60m |
| Earnings (TTM) | د.ت13.12m |
| Revenue (TTM) | د.ت115.13m |
17.8x
P/E Ratio2.0x
P/S RatioIs UMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UMED income statement (TTM) | |
|---|---|
| Revenue | د.ت115.13m |
| Cost of Revenue | د.ت55.01m |
| Gross Profit | د.ت60.13m |
| Other Expenses | د.ت47.01m |
| Earnings | د.ت13.12m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 52.22% |
| Net Profit Margin | 11.39% |
| Debt/Equity Ratio | 53.0% |
How did UMED perform over the long term?
See historical performance and comparison